GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Hold” from Analysts

by · The Cerbat Gem

Shares of GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $44.1250.

A number of research firms recently commented on GSK. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Jefferies Financial Group restated a “buy” rating on shares of GSK in a report on Monday, October 27th. Weiss Ratings restated a “buy (b)” rating on shares of GSK in a research note on Wednesday, November 26th. Bank of America upgraded shares of GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday, November 25th. Finally, Cfra set a $53.00 price objective on shares of GSK in a report on Thursday, October 30th.

Check Out Our Latest Analysis on GSK

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GSK. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of GSK in the 2nd quarter valued at $25,000. HHM Wealth Advisors LLC lifted its stake in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 460 shares during the period. CNB Bank bought a new position in GSK in the third quarter valued at about $31,000. Costello Asset Management INC acquired a new stake in GSK in the first quarter worth about $31,000. Finally, SOA Wealth Advisors LLC. raised its holdings in GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 605 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Up 2.4%

Shares of GSK stock opened at $48.34 on Friday. GSK has a 12-month low of $31.72 and a 12-month high of $48.69. The stock has a market capitalization of $98.15 billion, a P/E ratio of 13.65, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. The company has a 50-day simple moving average of $45.25 and a 200 day simple moving average of $41.31. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK – Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. The firm had revenue of $11.35 billion for the quarter, compared to analyst estimates of $8.21 billion. GSK had a net margin of 17.16% and a return on equity of 51.07%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Research analysts expect that GSK will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be issued a $0.4171 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.5%. GSK’s dividend payout ratio (DPR) is currently 46.05%.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Featured Articles